Hospital Universitario Rey Juan Carlos
- Address
- lock Available on a paid plan
Oncology and Hematologic Malignancies
At Hospital Universitario Rey Juan Carlos in Móstoles, a major focus is on neoplasms, especially multiple myeloma and breast cancer. The studies are aimed at comparing new treatment combinations, improving remission rates, and extending disease control for patients with relapsed or newly diagnosed cancer.
- New approaches for newly diagnosed multiple myeloma in patients eligible for stem cell transplant
- Treatment comparisons in relapsed/refractory multiple myeloma to improve survival outcomes
- Studies in high-risk HER2-positive breast cancer and hormone receptor-positive, HER2-negative early breast cancer
These trials reflect a strong effort to refine cancer therapy and test whether newer regimens can improve effectiveness while supporting better long-term outcomes.
Respiratory, Cardiovascular, and Critical Care
The site also conducts research in respiratory tract diseases, cardiovascular diseases, and critical illness. Current work includes studies on community-acquired pneumonia, acute pulmonary embolism, and sedation strategies for patients requiring intensive care support.
- Evaluating protection against vaccine-type community-acquired pneumonia
- Testing supportive treatment for acute pulmonary embolism
- Comparing sedation approaches in critically ill patients on mechanical ventilation
These investigations are designed to improve treatment effectiveness, patient safety, and day-to-day care in acute hospital settings.
Immune, Allergic, and Endocrine-Related Research
Research in immune system diseases includes studies for chronic inducible urticaria, while other work explores thyroid cancer with a focus on identifying markers that may help predict response to treatment. Together, these trials aim to improve both symptom control and personalized care.
- Testing a new option for chronic inducible urticaria in adults not well controlled with standard therapy
- Exploring biomarker-guided treatment for radioactive-iodine refractory differentiated thyroid cancer
- Supporting more tailored management of immune-mediated and endocrine oncology conditions
This area shows a clear interest in diagnostics and targeted treatment development, especially where current options leave patients with unmet needs.
Women’s Health and Urogenital Disorders
The research portfolio at this hospital also covers female urogenital diseases and pregnancy complications. Studies include care for stress or mixed urinary incontinence in older women and prevention strategies for preeclampsia during pregnancy.
- Investigating new options for urinary incontinence in women over 50 who have not responded to conventional care
- Evaluating a preventive approach for preterm preeclampsia
- Improving management of obstetric and pelvic health conditions
These trials are focused on practical clinical questions that may help improve quality of life and maternal health outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 62 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hospital Universitario Rey Juan Carlos
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Acetylsalicylic Acid Discontinuation Between Weeks 24 and 26 for Prevention of Preterm Preeclampsia in Pregnant Women at High Risk | Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca | Phase I | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bortezomib | 3 | Unknown | 2020-05-15 | 2022-10-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.